Evaluation of N1539 Following Major Surgery

NCT02720692 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 722

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.

Conditions

  • Pain, Post-operative

Interventions

DRUG

N1539

DRUG

Intravenous Placebo

Sponsors & Collaborators

  • Baudax Bio

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-03-31
Completion
2017-05-31

Countries

  • United States
  • Australia
  • Canada
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02720692 on ClinicalTrials.gov